Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 72
Filter
1.
Climacteric ; 27(3): 314-320, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38318796

ABSTRACT

OBJECTIVE: The prevalence of frailty has been related to menopause. Our main objective was to investigate whether single nucleotide polymorphisms (SNPs) of the estrogen receptor (ER) ERα and ERß genes were related to the frailty phenotype in a population of community-dwelling postmenopausal women. METHODS: A cross-sectional study was performed in which we selected five SNPs, three in the ERα gene and two in the ERß. Linear regression was used to estimate the percentage of phenotypic variance after adjusting for confounding variables. RESULTS: A total of 470 women (mean ± standard deviation age 63.83 ± 8.16 years) were included, of whom 137 women were frail. The SNP rs3798577 of the ERα gene was the only variant associated with frailty, but this significance faded in the multivariant analysis. Body mass index (p = 0.012), number of comorbidities (0 vs. ≥2, p = 0.002) and two reproductive variables, number of miscarriages (none vs. ≥2, p = 0.036) and of childbirths (one vs. ≥3, p = 0.008), were independently related to frailty. CONCLUSION: The five SNPs of the ERα and ERß genes tested were not correlated with frailty. Other SNPs of the ER warrant analysis to clarify whether variance in the gene response affects frailty status.


Subject(s)
Estrogen Receptor alpha , Estrogen Receptor beta , Frailty , Postmenopause , Aged , Female , Humans , Middle Aged , Alleles , Cross-Sectional Studies , Estrogen Receptor alpha/genetics , Estrogen Receptor beta/genetics , Frailty/genetics , Linear Models , Phenotype , Polymorphism, Single Nucleotide , Postmenopause/genetics
2.
Osteoporos Int ; 28(8): 2445-2455, 2017 08.
Article in English | MEDLINE | ID: mdl-28466138

ABSTRACT

This study represented a translational study that first compared gene expression of B cells of BM from ovariectomized and control mice, and then analyzed some of the differentially expressed genes in women. Results showed novel genetic associations with bone phenotypes and points to the CD80 gene as relevant in postmenopausal bone loss. INTRODUCTION: Osteoporosis is a multifactorial disease with a strong genetic component. However, to date, research into osteoporosis has only been able to explain a small part of its heritability. Moreover, several components of the immune system are involved in the regulation of bone metabolism. Among them, B cells occupy a prominent place. METHODS: The study consisted of two stages. In the first, gene expression in bone marrow B cells is compared between ovariectomized and SHAM control mice using microarrays. In the second, we studied the association of polymorphisms in some differentially expressed genes (DEG) in a cohort of postmenopausal women. RESULTS: The present study has found 2791 DEG (false discovery rate (FDR) <5%), of which 1569 genes were upregulated (56.2%) and 1122 genes (43.8%) were downregulated. Among the most altered pathways were inflammation, interleukin signaling, B cell activation, TGF-beta signaling, oxidative stress response, and Wnt-signaling. Sixteen DEG were validated by MALDI-TOF mass spectrometry or qPCR. The translational stage of the study genotyped nine single nucleotide polymorphisms (SNPs) of DEG or related and detected association with bone mineral density (BMD) (nominal P values), while adjusting for confounders, for SNPs in the CD80, CD86, and HDAC5 genes. In the logistic regression analysis adjusted for confounders, in addition to the SNPs in the aforementioned genes, the SNPs in the MMP9 and SOX4 genes were associated with an increased risk of osteoporosis. Finally, two SNPs (in the CD80 and SOX6 genes) were associated with an increased risk of bone fragility fracture (FF). However, after Bonferroni correction for multiple testing, only the association between CD80 with BMD and risk of osteoporosis remained significant. CONCLUSION: These results show that the use of animal models is an appropriate method for identifying genes associated with human bone phenotypes.


Subject(s)
B7-1 Antigen/genetics , Osteoporosis, Postmenopausal/genetics , Adult , Aged , Animals , Anthropometry/methods , B-Lymphocytes/metabolism , Bone Density/genetics , Bone Density/immunology , Disease Models, Animal , Female , Gene Expression Regulation , Genetic Association Studies , Genetic Predisposition to Disease , Genotype , Humans , Mice, Inbred C57BL , Middle Aged , Osteoporosis, Postmenopausal/immunology , Ovariectomy , Phenotype , Polymorphism, Single Nucleotide , Translational Research, Biomedical/methods
3.
Nutr Hosp ; 31 Suppl 1: 26-30, 2015 Feb 07.
Article in Spanish | MEDLINE | ID: mdl-25659051

ABSTRACT

The human microbiota is estimated to be 2.5-3.0 kg. Bacterial colonization starts during delivery, due to fetal contact with vaginal and intestinal maternal microorganisms. The oligosaccharides in human breast milk stimulate the growth of bacteria, which provide the optimal environment for intestinal mucosal immunity development. Additionally, breast milk has its own microbiota and it is altered in mastitis. The vagina is another important microenvironment. Vaginal dysbiosis leads to bacterial vaginosis and vaginal candidiasis, both of them very frequent in reproductive life. The probiotics are a potential and encouraging treatment for all microbiota alterations. Nevertheless, additional studies are required to confirm the benefits of probiotics.


La microbiota de cada individuo se estima en 2,5-3 kg de peso. La colonización bacteriana comienza en el momento del parto, por contacto del feto con la microbiota vaginal e intestinal de la madre. Los oligosacáridos de la leche materna estimulan el crecimiento de bacterias, que proporcionan el ambiente adecuado para el desarrollo de la inmunidad de la mucosa intestinal. Además, la leche materna es portadora de su propia microbiota, la cual se altera en las mastitis. La vagina constituye otro importante microambiente. Las disbiosis en esta zona conducen a la aparición de vaginosis bacteriana y candidiasis, siendo ambas una patología muy frecuente en la mujer en edad fértil. Los probióticos se presentan como tratamiento potencial y alentador de toda la patología asociada a alteraciones de la microbiota. Son necesarios más estudios que confirmen el beneficio de los probióticos en este campo.


Subject(s)
Gynecology , Obstetrics , Probiotics/therapeutic use , Female , Humans , Microbiota , Vagina/microbiology , Vaginosis, Bacterial/microbiology , Vaginosis, Bacterial/therapy
4.
Maturitas ; 75(2): 192-3, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23611497
5.
Maturitas ; 75(1): 7-21, 2013 May.
Article in English | MEDLINE | ID: mdl-23465359

ABSTRACT

OBJECTIVE: Coffee is a beverage used worldwide. It includes a wide array of components that can have potential implication on health. We have reviewed publications on the impact of coffee on a series of health outcomes. METHODS: Articles published between January 1990 and December 2012 were selected after crossing coffee or caffeine with a list of keywords representative of the most relevant health areas potentially affected by coffee intake. RESULTS: Caffeine, chlorogenic acids and diterpenes are important components of coffee. Tolerance often acts as a modulator of the biological actions of coffee. There is a significant impact of coffee on the cardiovascular system, and on the metabolism of carbohydrates and lipids. Contrary to previous beliefs, the various forms of arterial cardiovascular disease, arrhythmia or heart insufficiency seem unaffected by coffee intake. Coffee is associated with a reduction in the incidence of diabetes and liver disease. Protection seems to exist also for Parkinson's disease among the neurological disorders, while its potential as an osteoporosis risk factor is under debate. Its effect on cancer risk depends on the tissue concerned, although it appears to favor risk reduction. Coffee consumption seems to reduce mortality. CONCLUSION: The information gathered in recent years has generated a new concept of coffee, one which does not match the common belief that coffee is mostly harmful. This view is further supported by the discovery of a series of phyto-components with a beneficial profile. Reasonable optimism needs to be tempered, however, by the insufficiency of the clinical data, which in most cases stem from observational studies.


Subject(s)
Caffeine/pharmacology , Cardiovascular System/drug effects , Coffee , Animals , Carbohydrate Metabolism/drug effects , Central Nervous System Stimulants/pharmacology , Chlorogenic Acid/metabolism , Coffee/chemistry , Diterpenes/analysis , Drug Tolerance , Homocysteine/blood , Humans , Lipid Metabolism/drug effects
6.
Climacteric ; 15(5): 455-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22321028

ABSTRACT

ABSTRACT Objective To describe the effect of the intermittent administration of vaginal progesterone and a low-dose estradiol patch on endometrial stability, as assessed by the rate of amenorrhea and endometrial stimulation. Methods This was an open study in which 64 moderately symptomatic, postmenopausal women were treated in the outpatient clinic of our University Hospital for different intervals up to 1 year. The treatment consisted of a combination of patches delivering 25 µg/day estradiol and intravaginal pills containing 100 mg of micronized progesterone. Patches and pills were administered concomitantly in a twice-a-week protocol. The endometrial response was assessed by endovaginal ultrasound completed with suction biopsy when required. Results Both cumulative amenorrhea and no-bleeding rates increased progressively and reached 88.9% and 100.0%, respectively, by the 12th month. Isolated or repetitive episodes of bleeding, bleeding and spotting, or only spotting were reported by three, four, and 12 women, respectively. Endometrial thickness remained unaltered. Endometrium was atrophic in the seven women in whom a biopsy was performed. Conclusion The substantially reduced progestogen load determined by this combination achieved an acceptable incidence of spotting or bleeding when associated with a low estrogenic dose. There was no apparent endometrial stimulation. Additional studies are required to confirm this observation.


Subject(s)
Endometrium/drug effects , Estradiol/administration & dosage , Postmenopause , Progesterone/administration & dosage , Administration, Cutaneous , Administration, Intravaginal , Atrophy , Biopsy , Endometrium/diagnostic imaging , Endometrium/pathology , Estrogen Replacement Therapy/methods , Female , Humans , Middle Aged , Ultrasonography , Uterine Hemorrhage/epidemiology
7.
Maturitas ; 69(4): 312-21, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21665390

ABSTRACT

Cardiovascular disease is the leading determinant of mortality and morbidity in women. Functional foods are attracting interest as potential regulators of the susceptibility to disease. Supported by epidemiological evidence, chocolate has emerged as a possible modulator of cardiovascular risk. Chocolate, or cocoa as the natural source, contains flavanols, a subclass of flavonoids. The latter years have witnessed an increasing number of experimental and clinical studies that suggest a protective effect of chocolate against atherogenesis. Oxidative stress, inflammation, and endothelial function define three biological mechanisms that have shown sensitivity to chocolate. Moreover, the consumption of chocolate has been involved in the protective modulation of blood pressure, the lipid profile, the activation of platelets, and the sensitivity to insulin. Dark chocolate seems more protective than milk or white chocolate. Despite this array of benefits, there is a lack of well designed clinical studies demonstrating cardiovascular benefit of chocolate. The high caloric content of chocolate, particularly of some less pure forms, imposes caution before recommending uncontrolled consumption.


Subject(s)
Cacao/chemistry , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Flavonols/therapeutic use , Functional Food , Phytotherapy , Plant Preparations/therapeutic use , Animals , Cardiovascular Agents/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Flavonols/pharmacology , Humans , Inflammation/drug therapy , Insulin/metabolism , Lipids/blood , Plant Preparations/pharmacology , Platelet Activation/drug effects
8.
Osteoporos Int ; 22(5): 1451-8, 2011 May.
Article in English | MEDLINE | ID: mdl-20577873

ABSTRACT

SUMMARY: We have analysed the association of single-nucleotide polymorphisms (SNPs) in CD40 and CD40L genes with bone mineral density (BMD) in our women. Results showed that women with TT genotype for rs1883832 (CD40) and for rs1126535 (CD40L) SNPs displayed reduced BMD and increased risk for osteopenia/osteoporosis. Our data notwithstanding, the results need to be replicated. INTRODUCTION: Recent data have revealed that the CD40/CD40L system can be implicated in bone metabolism regulation. Moreover, we previously demonstrated that rs1883832 in the CD40 gene was significantly associated with BMD and osteoporosis risk. The objective of the present work was to determine whether polymorphisms in CD40 and CD40L genes are associated with BMD and osteoporosis risk. METHODS: We conducted an association study of BMD values with SNPs in CD40 and CD40L genes in a population of 811 women of which 693 and 711 had femoral neck (FN) and lumbar spine (LS) densitometric studies, respectively. RESULTS: Women with the TT genotype for rs1883832 (CD40) showed a reduction in FN-BMD (P = 0.005) and LS-BMD (P = 0.020) when compared with women with the CC/CT genotype. Moreover, we found that rs1126535 (CD40L) was significantly associated with LS-BMD so that women with the TT genotype displayed lower BMD (P = 0.014) than did women with the CC/CT genotype. Interestingly, we have found a strong interaction between polymorphisms in these genes. Thus, women with the TT genotype for both rs1883832 and rs1126535 SNPs (TT + TT women) showed a lower age-adjusted BMD (Z-score) for FN (P = 0.0007) and LS (0.007) after adjusting by years since menopause, body mass index, smoking and menopausal status, densitometer type, hormone replacement therapy (HRT) use and HRT duration and after making the Bonferroni adjustment for multiple comparisons than did the remaining women. Logistic regression analysis adjusted by these covariates showed that TT + TT women had increased risk for FN (odds ratio (OR) = 2.76; P = 0.006) and LS (OR = 2.39; P = 0.020) osteopenia or osteoporosis than did the other women. CONCLUSIONS: Our results suggest that interaction between genetic variants in the CD40 and CD40L genes exerts a role on BMD regulation. Further studies, which we welcome, are needed to replicate these data in other populations.


Subject(s)
CD40 Antigens/genetics , CD40 Ligand/genetics , Osteoporosis, Postmenopausal/genetics , Absorptiometry, Photon/methods , Aged , Anthropometry/methods , Bone Density/genetics , Female , Femur Neck/physiopathology , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Polymorphism, Single Nucleotide
9.
Climacteric ; 14(1): 41-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20443717

ABSTRACT

OBJECTIVES: Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture medium by enzyme immunoassay. Gene expression of prostacyclin synthase and thromboxane synthase was analyzed by quantitative real-time polymerase chain reaction. Expression of prostacyclin synthase protein was analyzed by Western blot. RESULTS: Both progestogens decreased thromboxane A2 release after 24 h. Protein and gene expression of prostacyclin synthase were increased after exposure to both progestogens, without changes in thromboxane synthase expression. These effects induced by progestogens were mediated through progesterone receptors, since they were decreased in the presence of the progesterone receptor antagonist RU486. The cyclo-oxygenase-1 selective inhibitor reduced thromboxane release. CONCLUSION: Progesterone and medroxyprogesterone acetate decreased HUVEC thromboxane release in a progesterone receptor-dependent manner, without changes in thromboxane synthase expression and enhanced prostacyclin synthase gene and protein expression.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Endothelial Cells/metabolism , Medroxyprogesterone Acetate/pharmacology , Progesterone/pharmacology , Progestins/pharmacology , Thromboxane A2/metabolism , Blotting, Western , Cells, Cultured , Cyclooxygenase Inhibitors/pharmacology , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Dose-Response Relationship, Drug , Gene Expression , Hormone Antagonists/pharmacology , Humans , Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , Mifepristone/pharmacology , Polymerase Chain Reaction , Pyrazoles/pharmacology , RNA, Messenger/metabolism , Thromboxane B2/metabolism , Thromboxane-A Synthase/genetics , Thromboxane-A Synthase/metabolism , Umbilical Veins/cytology
10.
Climacteric ; 12(4): 286-300, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19415543

ABSTRACT

OBJECTIVE: Osteoporosis is a chronic disease that accelerates after menopause in many women. Most of the pharmacologic attempts to control the disease, such as hormone therapy, have emphasized the constraint of bone resorption. Since recent years have witnessed important advances in the field of bone formation, this review aims to update the present knowledge on the mechanisms affecting osteoblastogenesis and on the therapeutic results achieved by recently approved drugs. METHOD: We sought peer-reviewed, full-length basic and clinical articles published between 1995 and May 2008 using a PubMed search strategy, with the terms osteoporosis and osteoblast, osteoporosis and strontium ranelate, and osteoporosis and parathyroid hormone (PTH). This search was further supplemented by a hand-search of reference lists of selected review papers. After crossing-cleaning the reference lists, some 800 articles were selected. Articles on regulators of osteoblast differentiation and function, together with well-designed clinical studies, were surveyed. RESULTS: A complex network of systemic and local factors regulates osteoblastogenesis. Advances in fracture protection have been published in clinical studies with PTH. Some investigators claim an anabolic effect for strontium ranelate, which also confers protection against fracture. CONCLUSION: The control of bone formation offers new clinical potential. Stimulation of bone formation by PTH has translated into fracture protection. The action of strontium ranelate has been claimed to be mediated by some level of bone formation, but this hypothesis still needs clarification.


Subject(s)
Osteoblasts/physiology , Osteogenesis , Osteoporosis, Postmenopausal/drug therapy , Aged , Animals , Bone Density Conservation Agents/therapeutic use , Cell Differentiation/drug effects , Cell Differentiation/genetics , Female , Fractures, Bone/prevention & control , Gene Expression Regulation , Humans , Middle Aged , Organometallic Compounds/therapeutic use , Osteoblasts/cytology , Osteoblasts/drug effects , Osteogenesis/drug effects , Osteogenesis/physiology , Parathyroid Hormone/therapeutic use , Thiophenes/therapeutic use
11.
Climacteric ; 10(2): 97-111, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17453858

ABSTRACT

Coronary heart disease (CHD) is the leading cause of death in women in most countries. Atherosclerosis is the main biological process determining CHD. Clinical data support the notion that CHD is sensitive to estrogens, but debate exists concerning the effects of the hormone on atherosclerosis and its complications. Selective estrogen receptor modulators (SERMs) are compounds capable of binding the estrogen receptor to induce a functional profile distinct from estrogens. The possibility that SERMs may shift the estrogenic balance on cardiovascular risk towards a more beneficial profile has generated interest in recent years. There is considerable information on the effects of SERMs on distinct areas that are crucial in atherogenesis. The complexity derived from the diversity of variables affecting their mechanism of action plus the differences between compounds make it difficult to delineate one uniform trend for SERMs. The present picture, nonetheless, is one where SERMs seem less powerful than estrogens in atherosclerosis protection, but more gentle with advanced forms of the disease. The recent publication of the Raloxifene Use for The Heart (RUTH) study has confirmed a neutral effect for raloxifene. Prothrombotic states may favor occlusive thrombi at sites occupied by atheromatous plaques. Platelet activation has received attention as an important determinant of arterial thrombogenesis. Although still sparse, available evidence globally suggests neutral or beneficial effects for SERMs.


Subject(s)
Coronary Disease/prevention & control , Selective Estrogen Receptor Modulators/pharmacology , Animals , Coronary Artery Disease/prevention & control , Endothelium, Vascular/drug effects , Estrogens/physiology , Hemostasis/drug effects , Hemostasis/physiology , Humans , Lipids/blood , Risk Factors
12.
Hum Reprod ; 21(4): 880-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16459351

ABSTRACT

BACKGROUND: Within the last few years, much evidence has been presented on the involvement of the immune system in certain types of bone loss, such as activated T cells in rheumatoid arthritis and in periodontitis. Estrogen deficiency induces bone loss; however, how this deficiency affects the immune system has not been sufficiently studied. METHODS: To evaluate the effects of estrogen withdrawal on the status and functionality of the immune system, mice were ovariectomized or sham-operated, and 5 weeks after surgery, when osteopenia had developed, several parameters were analysed in spleen and in bone marrow. We analysed bone turnover, cell phenotype by flow cytometry, cell function by cell proliferation assays, and the expression of several genes related to the process. RESULTS: Five weeks after ovariectomy, augmented osteoclastogenesis persisted in the bone marrow. In addition, the ovariectomized mice had more B-cells and CD3+ T-cells expressing the receptor activator of NF-kappaB ligand (CD3+/RANKL+). The ovariectomized mice had lower serum alkaline phosphatase activity, a normal amount of T cells, lower percentages of CD11b+ and CD51+ cells in the bone marrow, and a lower serum interferon-gamma level compared with sham-operated controls. CONCLUSIONS: The data suggest that, 5 weeks after ovariectomy, bone turnover remains imbalanced, with increased osteoclastogenesis and a decreased rate of bone formation. Moreover, there is an increase in B-cell formation, with normal and decreased percentages of T cells and myelomonocytic cells (CD11b+), respectively, in the bone marrow. Decreased serum interferon-gamma levels could be involved in the increased osteoclastogenesis found in the present work.


Subject(s)
B-Lymphocytes/immunology , Bone Diseases, Metabolic/immunology , Estrogens/deficiency , T-Lymphocytes/immunology , Alkaline Phosphatase/blood , Animals , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/pathology , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , Cell Proliferation , Female , Gene Expression , Interferon-gamma/blood , Mice , NF-kappa B/metabolism , Osteogenesis/physiology , Ovariectomy , Phenotype , Spleen/cytology , Uterus/pathology
13.
Hum Reprod ; 20(6): 1554-61, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15734756

ABSTRACT

BACKGROUND: The effects of progestogens on endothelial physiology are poorly studied. Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase (COX) in endothelium. We examined the effects of two clinically used progestogens, progesterone and medroxyprogesterone acetate (MPA), on prostacyclin production by cultured human umbilical vein endothelial cells (HUVEC) and the possible role of progesterone receptors and both COX enzymes. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or MPA and prostacyclin production was measured in culture medium. RESULTS: Both progestogens significantly increased prostacyclin release in a time- and dose-dependent manner, being higher than control after 24 h. Progesterone and MPA, both at 10 nmol/l, increased mRNA expression and protein content of both COX. All these effects were mediated through progesterone receptor activation, since they were abolished by treatment of cells with the progesterone receptor antagonist RU-486. Selective inhibitors of COX-1 and -2 (SC-560 and NS-398 respectively) reduced basal prostacyclin release, and eliminated increased production in response to progestogens. In combination with estradiol, progestogens had an additive effect without eliminating estradiol-induced prostacyclin production. CONCLUSIONS: Our results support the hypothesis that progesterone and MPA increased HUVEC prostacyclin production in a progesterone receptor-dependent manner, by enhancing COX-1 and COX-2 expression and activities.


Subject(s)
Endothelium, Vascular/metabolism , Epoprostenol/biosynthesis , Progestins/pharmacology , Cells, Cultured , Cyclooxygenase 1 , Cyclooxygenase 2 , Cyclooxygenase 2 Inhibitors , Cyclooxygenase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Estradiol/pharmacology , Humans , Medroxyprogesterone Acetate/pharmacology , Membrane Proteins , Mifepristone/pharmacology , Nitrobenzenes/pharmacology , Progesterone/pharmacology , Prostaglandin-Endoperoxide Synthases/drug effects , Prostaglandin-Endoperoxide Synthases/genetics , Pyrazoles/pharmacology , Receptors, Progesterone/antagonists & inhibitors , Receptors, Progesterone/metabolism , Sulfonamides/pharmacology , Umbilical Veins/cytology , Umbilical Veins/drug effects
14.
Reprod Fertil Dev ; 16(3): 373-8, 2004.
Article in English | MEDLINE | ID: mdl-15304211

ABSTRACT

The aim of the present study was to determine, in the mouse, whether maintaining females as virgins until an advanced reproductive age was associated with decreased reproductive performance and reproductive lifespan compared with females of the same age that were first mated with males at an earlier reproductive age. Randomly selected virgin hybrid (C57BL/6JIco female x CBA/JIco male) female mice were housed individually with a randomly selected 12- to 14-week-old hybrid male either at the age of 28 weeks (normal breeding group; n = 20) or 51 weeks (delayed breeding group; n = 23) for the rest of their reproductive life. Females were checked once daily to determine the day of parturition and to record the litter size and gender of pups at birth for each consecutive litter. At weaning, offspring were weighed and killed. Delayed breeding was associated with smaller litter sizes, both at birth and at weaning, a higher bodyweight of pups at weaning, a higher percentage of litters with at least one newborn pup cannibalised, earlier cessation of female reproductive life and a higher mortality rate of dams during the breeding period. These results show that delayed breeding in the mouse is associated with decreased reproductive performance and a shorter reproductive lifespan compared with females bred at an earlier reproductive age.


Subject(s)
Reproduction/physiology , Sexual Maturation , Age Factors , Animals , Breeding , Female , Litter Size , Male , Mice , Mice, Inbred Strains
15.
Calcif Tissue Int ; 74(2): 143-9, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14648010

ABSTRACT

In order to assess similarities and differences in women that suffer surgical versus natural menopause, a series of bone, clinical, and biochemical parameters was assayed in a clinical sample of 35 women with surgical menopause and 112 women with natural menopause. Biochemical parameters included hormones [parathyroid hormone (PTH) and the sex steroids estradiol and testosterone] and several markers of bone turnover measured in urine (N-telopeptide and calcium/creatinine ratio) or serum (osteocalcin, total alkaline phosphatase, total and ionic calcium, phosphate, and magnesium). In addition to type of menopause, women were divided by years since menopause (ysm 2). To detect differences and relationships between variables, ANOVA, ANCOVA, and linear regression analyses were used. Only N-telopeptide, one resorption marker, was significantly affected by the variable years since menopause 2 ( P <0.01), but not by type of menopause. The age-corrected level of PTH was significantly decreased in the surgical menopause group ( P < 0.05). In conclusion, type of menopause did not impose significant differences in bone turnover markers. PTH, one powerful resorption hormone, was diminished in surgical menopause.


Subject(s)
Biomarkers/analysis , Menopause, Premature/blood , Menopause, Premature/urine , Osteogenesis/physiology , Parathyroid Hormone/blood , Absorptiometry, Photon , Bone Density , Bone and Bones/diagnostic imaging , Bone and Bones/metabolism , Collagen/urine , Collagen Type I , Female , Humans , Middle Aged , Peptides/urine
16.
Theriogenology ; 57(5): 1539-50, 2002 Mar 15.
Article in English | MEDLINE | ID: mdl-12054212

ABSTRACT

This study aims to ascertain whether oral administration of pharmacological doses of Vitamins C and E has any detrimental effect on reproductive fitness of female mice. We fed hybrid female mice from the first day of weaning a standard diet supplemented or not supplemented with pharmacological doses of Vitamins C and E. At the age of 28 weeks, we individually caged females with a male for the rest of their reproductive life. We performed a series of mating experiments to ascertain the number of oocytes ovulated and the potential for embryo development in vitro to the blastocyst stage and in vivo to Day 12 of gestation. The antioxidant diet decreased the frequency of litters, litter size, total number of offspring born and survival of male pups to weaning. This effect was associated with lower number of corpora lutea in the left ovary, decreased percentage of viable fetuses, and higher number of fetal resorptions in the left uterine horn when compared to the control group. The strategy of supplementing the diet with antioxidant vitamins to prevent the age associated decrease in reproductive potential should not be implemented in human beings until a safe and efficient diet is designed.


Subject(s)
Antioxidants/adverse effects , Ascorbic Acid/adverse effects , Ovary/drug effects , Reproduction/drug effects , Uterus/drug effects , Vitamin E/adverse effects , Animals , Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Blastocyst/physiology , Body Weight , Dietary Supplements , Embryonic and Fetal Development , Female , Fertilization in Vitro , Gestational Age , Litter Size , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Oocytes/physiology , Ovary/physiology , Ovulation , Uterus/physiology , Vitamin E/administration & dosage , Weaning
17.
Theriogenology ; 57(2): 869-81, 2002 Jan 15.
Article in English | MEDLINE | ID: mdl-11991390

ABSTRACT

The present study aims to analyze the effect of dietary supplementation with a mixture of Vitamins C and E on fertilization and later development of tertiary butyl hydroperoxide (tBH)-treated mouse oocytes and on parthenogenetic activation of freshly ovulated mouse oocytes. We fed hybrid mice a standard diet supplemented or not supplemented with Vitamins C and E from the first day of weaning until the age of 12 weeks. We noted no significant effect of diet on fertilization rate, percentage of total and hatching blastocysts, total number of cells, mitotic index and percentage of apoptotic nuclei at 120 h post-insemination of oocytes incubated for 15 min in the presence of 0, 1, 5 and 10 microM tBH. Furthermore, diet did not affect the percentage of activated oocytes after treatment with Ca2+ ionophore, acid Tyrode's solution or ethanol. The percentage of parthenogenetically activated oocytes that progressed to the pronuclear stage was significantly higher in the antioxidant group. Oocytes from antioxidant females exhibited a significantly lower mitogen-activated protein kinase (MAPK) activity than oocytes from control females. We detected no significant differences between groups in M-phase-promoting factor (MPF) activity. These results show that oral administration of antioxidants decreases MAPK activity and increases the probability of reaching the pronuclear stage after parthenogenetic activation.


Subject(s)
Ascorbic Acid/administration & dosage , Fertilization/drug effects , Oocytes/drug effects , Parthenogenesis , Vitamin E/administration & dosage , tert-Butylhydroperoxide/pharmacology , Animals , Culture Techniques , Dietary Supplements , Embryonic and Fetal Development , Female , Fertilization in Vitro , Male , Maturation-Promoting Factor/analysis , Mesothelin , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mitogen-Activated Protein Kinases/analysis , Oocytes/chemistry , Oocytes/physiology , Weaning
18.
Biol Reprod ; 65(1): 141-50, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11420234

ABSTRACT

The present study aims to shed light on the origin of abnormal oocytes ovulated by aged females. In order to reach this goal, cellular and morphological traits of ovulated oocytes from hybrid (C57Bl/6JIco female x CBA/JIco male) female mice retrieved after exogenous ovarian stimulation at the age of 12, 40-42, 50-52, or 57-62 wk were analyzed. Aging of female mice was associated with 1) decreased number of ovulated oocytes; 2) increased percentage of cumulus-free oocytes; 3) raised percentage of oocytes with intracellular mitochondrial aggregates; 4) reduced percentage of oocytes displaying a normal distribution of chromosomes in the metaphase-II plate; 5) increased percentage of normal oocytes exhibiting a DNA-containing polar body (PB); 6) higher percentage of oocytes with chromosome scattering; 7) increased percentage of chromosome-scattered oocytes without a DNA-containing PB and with intracytoplasmic mitochondrial aggregates; 8) raised percentage of oocytes exhibiting chromosome decondensation; 9) lower percentage of chromosome-decondensed oocytes lacking both a DNA-containing PB and intracytoplasmic mitochondrial aggregates; 10) increased percentage of abnormal/degenerated oocytes; 11) reduced percentage of abnormal/degenerated oocytes displaying cellular fragmentation; and 12) higher percentage of abnormal/degenerated oocytes with mitochondrial aggregates exhibiting no nuclear/chromosomal DNA fluorescence, cellular fragmentation, milky or dark cytoplasm, or cellular remains enclosed by the zona pellucida. Although several studies suggest aging females may ovulate aged or overripened oocytes, these data support the hypothesis that old females ovulate an increased percentage of atretic/apoptotic oocytes coming from rescued follicles that would have become atretic earlier in life.


Subject(s)
Aging/physiology , Oocytes/physiology , Ovary/physiology , Animals , Chromosomes/ultrastructure , DNA/biosynthesis , DNA/genetics , Female , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Oocytes/ultrastructure , Ovary/cytology , Pregnancy
19.
Maturitas ; 38(3): 287-95, 2001 May 30.
Article in English | MEDLINE | ID: mdl-11358646

ABSTRACT

OBJECTIVES: To disclose if oral estradiol (E(2)), alone or in combination with natural progesterone (P) or medroxyprogesterone acetate (MPA), may modify the oxidizability of low density lipoprotein (LDL), and if the effect is achieved at physiological dosages. LDL oxidizability was assessed by the resistance to oxidation by copper and by the particle size profile, since small particles have increased oxidation susceptibility. METHODS: Thirty-three women received two consecutive, two-month length doses of 1 and 2 mg/day of oral E(2). They were then randomly assigned to a fourteen-day treatment of 2 mg/day E(2) plus either 300 mg/day P or 5 mg/day MPA. A parallel group of experiments was performed on a pool of baseline plasma, where hormones were added at the desired concentration. Lipoprotein levels, resistance of LDL to oxidation, and LDL particle diameter, were measured at baseline and after each treatment. RESULTS: Estradiol reduced LDL levels and increased high density lipoprotein (HDL) and triglycerides. P abolished these changes, whereas MPA only reversed the increase of HDL. Estradiol protected LDL from oxidation in a dose-dependent manner, although only at pharmacological concentrations (1 microM or higher). Both P and MPA were inert at either physiological or pharmacological concentrations. The size of the LDL particles remained unaffected except under MPA, in which it was reduced. CONCLUSIONS: Estradiol has a protective effect against LDL oxidation, although only at pharmacological dosages. P and MPA did not limit the E(2) action. The size of the LDL particles remained unaltered after each E(2) dose, but MPA, and not P, was associated with a diminution.


Subject(s)
Cholesterol, LDL/drug effects , Estradiol/pharmacology , Hormone Replacement Therapy , Medroxyprogesterone Acetate/pharmacology , Progesterone/pharmacology , Administration, Oral , Cholesterol, LDL/blood , Cholesterol, LDL/chemistry , Dose-Response Relationship, Drug , Estradiol/administration & dosage , Female , Humans , Medroxyprogesterone Acetate/administration & dosage , Middle Aged , Oxidation-Reduction , Particle Size , Postmenopause , Progesterone/administration & dosage
20.
J Assist Reprod Genet ; 18(12): 650-4, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11808846

ABSTRACT

PURPOSE: To ascertain whether advanced maternal age at birth is associated with offspring infertility. METHODS: A written questionnaire was completed by infertile couples attending our clinic in the presence of a researcher. RESULTS: Maternal age at birth (odds ratio 1.236, 95% CI 1.100-1.388) and birth order of all respondents and their respective siblings (odds ratio 0.551, 95% CI 0.351-0.865) were significant predictors of male infertility. The probability of a man being infertile increased as mother's age at birth increased (regression coefficient +/- standard error 0.212 +/- 0.059; P < 0.001), but decreased as birth order increased (regression coefficient +/- standard error -0.596 +/- 0.230; P = 0.010). CONCLUSIONS: Delayed motherhood may enhance the probability of sons to be infertile. The probability of a man being infertile would be greater if he comes from a small family than if he comes from a large family.


Subject(s)
Infertility, Male , Maternal Age , Pregnancy, High-Risk , Female , Humans , Infertility, Male/congenital , Male , Regression Analysis , Risk Factors , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...